TY  - Type of reference 
TI  - Open Innovation as A Driver of Industrial and Organizational Mutations during the Pandemic: Case Study of the Pharmaceutical Sector 
AU  - Camille Aouinaït
 
AU  - Son Thi Kim Le
 
AU  - Michelle Mongo
 
AU  - Laurent Adatto 
AB  - The Covid-19 pandemic emphasized health system failures, lack of medical devices, and new ways to innovate, in particular based on Open Innovation. An exploratory case study that exemplified the value of implementing Open Innovation in the pandemic context will be shown. The research question is: how has Open Innovation boosted healthcare production to cope with the pandemic? The case study of the Pfizer/BioNTech pharmaceutical alliance is methodologically built on full referencing and systematic analysis of published articles, scientific documents, and reports related to Open Innovation. Based on this case study, we will be able to show that in the context of pandemic emergency, Open Innovation is an efficient vector that allows expanding partnerships to accelerate R&D and production operations. 
DO  - 10.21494/ISTE.OP.2025.1270 
JF  - Technology and Innovation 
KW  - Open Innovation, Open Source, Covid-19 Pandemic, Pharmaceutical Industry, Innovation ouverte, Source ouverte, Pandémie de Covid-19, Industrie pharmaceutique,  
L1  - https://www.openscience.fr/IMG/pdf/iste_techinn25v10n2_9.pdf 
LA  - en 
PB  - ISTE OpenScience 
DA  - 2025/03/23 
SN  - 2399-8571 
TT  - L’innovation ouverte comme moteur des mutations industrielles et organisationnelles pendant la pandémie : Etude de cas du secteur pharmaceutique 
UR  - https://www.openscience.fr/Open-Innovation-as-A-Driver-of-Industrial-and-Organizational-Mutations-during 
IS  - Issue 2 
VL  - 10 
ER  -